Circulation, Vol 67, 1117-1123, Copyright © 1983 by American Heart Association
The antiarrhythmic efficacy and safety of oral flecainide acetate and
quinidine sulfate were compared in a double-blind, 16-center parallel trial
involving 280 patients with chronic premature ventricular complexes (PVCs).
Eighty-five percent of the flecainide patients had at least 80% suppression
of PVCs, vs 57% of the quinidine patients (p less than 0.0001). Sixty-eight
percent of the flecainide patients met the above criterion and also had
complete suppression of couplets and beats of ventricular tachycardia, vs
33% of the quinidine patients (p less than 0.0001). PR and QRS intervals
were prolonged by flecainide without clinical consequence, but they were
not substantially affected by quinidine (p less than 0.0001). Quinidine
prolonged JT (QT minus QRS) intervals significantly more than flecainide (p
less than 0.05). Nineteen of 141 flecainide patients and 21 of 139
quinidine patients discontinued therapy because of side effects (p greater
than 0.50). Flecainide side effects included dizziness, blurred vision,
headache and nausea. Quinidine side effects included diarrhea, nausea,
headache and dizziness. Flecainide was more effective than quinidine in
suppressing chronic ventricular arrhythmias (especially complex forms), and
thus is an important new antiarrhythmic agent.
ARTICLES
Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial
This article has been cited by other articles:
![]() |
R. LAL, P. D. CHAPMAN, G. V. NACCARELLI, K. B. SCHECHTMAN, R. L RINKENBERGER, P. J. TROUP, S. S. KIM, A. H. DOUGHERTY, and R. RUFFY Flecainide in the Treatment of Nonsustained Ventricular Tachycardia Ann Intern Med, October 1, 1986; 105(4): 493 - 498. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1983 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |